Arsenic trioxide - Phebra

Drug Profile

Arsenic trioxide - Phebra

Alternative Names: Phenasen

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phebra
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia

Most Recent Events

  • 14 Jun 2017 Phase-I clinical trials in Acute promyelocytic leukaemia (First-line therapy) in Australia, New Zealand (PO, Capsule) (ACTRN12616001022459)
  • 16 Mar 2017 Arsenic trioxide - Phebra (Capsule) receives Orphan Drug status for Acute promyelocytic leukaemia in Australia
  • 01 Jan 2017 Preclinical trials in Acute promyelocytic leukaemia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top